"24501" . . "1"^^ . "Kombina\u010Dn\u00ED hypolipidemick\u00E1 l\u00E9\u010Dba" . . "Sou\u010Dasn\u00E9 pod\u00E1v\u00E1n\u00ED v\u00EDce ne\u017E jednoho l\u00E9\u010Diva k ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika z\u00E1sahem do metabolizmu s\u00E9rov\u00FDch lipoprotein\u016F nen\u00ED ve srovn\u00E1n\u00ED s postupy v l\u00E9\u010Db\u011B arteri\u00E1ln\u00ED hypertenze \u010Di diabetu zdaleka tak \u010Dasto vyu\u017E\u00EDv\u00E1no. Z\u00E1kladem hypolipidemick\u00E9 l\u00E9\u010Dby je ve velk\u00E9 p\u0159evaze p\u0159\u00EDpad\u016F statin, k n\u011Bmu\u017E bude v p\u0159\u00EDpad\u011B nutnosti dal\u0161\u00EDho sn\u00ED\u017Een\u00ED LDL cholesterolu mo\u017En\u00E1 kombinace s ezetimibem nebo sekvestranty \u017Elu\u010Dov\u00FDch kyselin - prysky\u0159icemi. U sm\u00ED\u0161en\u00E9 dyslipidemie zejm\u00E9na v kontextu diabetu 2. typu lze vyu\u017E\u00EDt kombinace statinu s fibr\u00E1tem p\u0159\u00EDpadn\u011B farmakologick\u00FDmi d\u00E1vkami omega- 3 mastn\u00FDch kyselin. Naproti tomu v\u00FDsledky posledn\u00EDch klinick\u00FDch studi\u00ED uk\u00E1zaly, \u017Ee niacin sv\u00E9 m\u00EDsto v hypolipidemick\u00E9 l\u00E9\u010Db\u011B nad\u00E1le nenajde. Velmi zaj\u00EDmav\u00E9 a slibn\u00E9 jsou v\u00FDsledky prob\u00EDhaj\u00EDc\u00EDch studi\u00ED s n\u011B-kte-r\u00FDmi nov\u00FDmi hypolipidemiky - p\u0159edev\u0161\u00EDm monoklon\u00E1ln\u00ED protil\u00E1tky proti PCSK9 nab\u00EDzej\u00ED dosud nev\u00EDdan\u00E9 mo\u017Enosti ovlivn\u011Bn\u00ED lipidogramu. I jejich m\u00EDsto bude p\u0159edev\u0161\u00EDm v kombina\u010Dn\u00EDch farmakologick\u00FDch re\u017Eimech. Troj- a v\u00EDce kombinace hypolipidemik sice nemaj\u00ED oporu v datech z klinick\u00FDch studi\u00ED, ale je vhodn\u00E9 na n\u011B v individu\u00E1ln\u00EDch p\u0159\u00EDpadech myslet." . . . . "2336-288X" . "[71AEAAC19463]" . . "PCSK9 inhibitors; resins; ezetimibe; fibrates; statins; lipid lowering combination; dyslipidemia; Cardiovascular risk"@en . "Kombina\u010Dn\u00ED hypolipidemick\u00E1 l\u00E9\u010Dba" . "11110" . "Kombina\u010Dn\u00ED hypolipidemick\u00E1 l\u00E9\u010Dba"@cs . . . "RIV/00216208:11110/14:10286926" . "Kombina\u010Dn\u00ED hypolipidemick\u00E1 l\u00E9\u010Dba"@cs . . "RIV/00216208:11110/14:10286926!RIV15-MSM-11110___" . . . "http://www.prolekare.cz/linkout/50704" . "V" . "16" . "Combination hypolipidemic therapy"@en . "CZ - \u010Cesk\u00E1 republika" . . . "Kardiologick\u00E1 revue - Intern\u00ED medic\u00EDna" . "Combination hypolipidemic therapy"@en . "6"^^ . . . . . . "Vrabl\u00EDk, Michal" . . "CO-admoinistration of more than one drug targeting cardiovascular risk by impacting on serum lipoprotein matabolism is used much less than combinations in the treatment of arterial hypertension or type 2 diabetes. The most commonly used lipid lowering drugs are statins, which may combined with ezetimibe or bile acid sequestrants when a more significant decrease of LDL-cholesterol is required. In mixed dyslipidemia, particularly in the context of type 2 diabetes, statins may be combined with ibrates, or even with pharmacological doses of omega-3 fatty acids. On the contrara, the results of the lates clinical trials have shown that niacin has lost its position in the treatment of dyslipidemia. The results of clinical trials with brand-new molecules used in the treatment of dyslipidemia hold great promise - in particular, monoclonal antibodies against PCSK9 seem to offer unprecedented possibilities of impacting on lipid metabolism. However, they will also be present mainly within the combination lipid lowering regimns. Triple- and multiple-lipid lowering combos are not supported by clinical trial data, but they might be used in individual cases for the benefit of our patients."@en . "Sou\u010Dasn\u00E9 pod\u00E1v\u00E1n\u00ED v\u00EDce ne\u017E jednoho l\u00E9\u010Diva k ovlivn\u011Bn\u00ED kardiovaskul\u00E1rn\u00EDho rizika z\u00E1sahem do metabolizmu s\u00E9rov\u00FDch lipoprotein\u016F nen\u00ED ve srovn\u00E1n\u00ED s postupy v l\u00E9\u010Db\u011B arteri\u00E1ln\u00ED hypertenze \u010Di diabetu zdaleka tak \u010Dasto vyu\u017E\u00EDv\u00E1no. Z\u00E1kladem hypolipidemick\u00E9 l\u00E9\u010Dby je ve velk\u00E9 p\u0159evaze p\u0159\u00EDpad\u016F statin, k n\u011Bmu\u017E bude v p\u0159\u00EDpad\u011B nutnosti dal\u0161\u00EDho sn\u00ED\u017Een\u00ED LDL cholesterolu mo\u017En\u00E1 kombinace s ezetimibem nebo sekvestranty \u017Elu\u010Dov\u00FDch kyselin - prysky\u0159icemi. U sm\u00ED\u0161en\u00E9 dyslipidemie zejm\u00E9na v kontextu diabetu 2. typu lze vyu\u017E\u00EDt kombinace statinu s fibr\u00E1tem p\u0159\u00EDpadn\u011B farmakologick\u00FDmi d\u00E1vkami omega- 3 mastn\u00FDch kyselin. Naproti tomu v\u00FDsledky posledn\u00EDch klinick\u00FDch studi\u00ED uk\u00E1zaly, \u017Ee niacin sv\u00E9 m\u00EDsto v hypolipidemick\u00E9 l\u00E9\u010Db\u011B nad\u00E1le nenajde. Velmi zaj\u00EDmav\u00E9 a slibn\u00E9 jsou v\u00FDsledky prob\u00EDhaj\u00EDc\u00EDch studi\u00ED s n\u011B-kte-r\u00FDmi nov\u00FDmi hypolipidemiky - p\u0159edev\u0161\u00EDm monoklon\u00E1ln\u00ED protil\u00E1tky proti PCSK9 nab\u00EDzej\u00ED dosud nev\u00EDdan\u00E9 mo\u017Enosti ovlivn\u011Bn\u00ED lipidogramu. I jejich m\u00EDsto bude p\u0159edev\u0161\u00EDm v kombina\u010Dn\u00EDch farmakologick\u00FDch re\u017Eimech. Troj- a v\u00EDce kombinace hypolipidemik sice nemaj\u00ED oporu v datech z klinick\u00FDch studi\u00ED, ale je vhodn\u00E9 na n\u011B v individu\u00E1ln\u00EDch p\u0159\u00EDpadech myslet."@cs . "6" . "1"^^ .